.svg)
Classiq とQuantum Intelligence Corp（韓国、QIC）が量子加速医薬品開発で提携
SEOUL, SOUTH KOREA and TEL AVIV, ISRAEL, April 4, 2024- Classiq, a leading quantum computing software company, and Quantum Intelligence Corp. (QIC, Korea) today announced the launch of innovative joint research to accelerate drug development by applying quantum computing to pharmacology. The collaboration is under the auspices of Classiq’s Quantum Computing For Life Sciences & Healthcare Center, launched with NVIDIA last year.
This new partnership is dedicated to utilizing the Classiq platform to explore the use of quantum computing in pharmacology for a wide range of predictive and analytical applications. This includes the discovery and design of novel drug candidates as well as the prediction of potential side effects and interactions. The partnership focuses on significantly enhancing the efficiency and accuracy of drug development by integrating Classiq's quantum computing platform with QIC's drug development platform.
“Quantum Intelligence diverges from the traditional route of biopharmaceutical companies, positioning it self more as a platform company powered by quantum and AI technology,” stated QIC's CEO, Hwan ho Choi, MD., PhD. “Through this unique collaborative approach, we aim to precisely identify potential side effects early on, reducing risks across all stages of drug development and clinical trials.”
QIC, a South Korean startup pioneering the QUEST-ADMET platform based on quantum computing and AI technologies, targets prediction of compound properties through electronic charge distribution algorithms, to efficiently assess therapeutic solution efficacy and safety of drug candidates.
Classiq offers a leading quantum development platform with unique technology enabling high-level abstraction that simplifies and accelerates development of efficient complex quantum software and applications. The Classiq platform’s built-in functions, GitHub repository and seamless execution on quantum computing hardware, will be key components in the research to develop pharmacology applications for research.
“This agreement marks a significant step towards a new era of accelerated drug development using quantum computing technology,” said Classiq’s CEO Nir Minerbi. “By combining Classiq's quantum computing technology with QIC's drug development platform, we target significant improvements in the efficiency and accuracy of drug development.”
Classiq について
Classiq 量子ソフトウェアのリーディングカンパニーであるテクノロジーズ社は、アルゴリズム設計から実行まで、量子コンピューティングへの入口を一本化した包括的なプラットフォーム（IDE、コンパイラ、OS）を提供しています。高レベルの記述式量子ソフトウェア開発環境は、あらゆるレベルの開発者の習熟度に対応し、量子プログラミングを自動化します。これにより、AI、ML、線形代数などのバックグラウンドを持つ幅広い人材が、量子物理学の深い専門知識を必要とすることなく、量子コンピューティングを活用することができます。Classiq 、量子コンピューティングへのアクセスを民主化し、幅広い量子ハードウェアへのアクセスを含め、量子コンピューティング革命を最大限に活用できるようにします。
高度な記述式の量子ソフトウェア開発環境は、あらゆるレベルの開発者の習熟度に対応し、量子プログラミングを自動化します。これによりAI、機械学習（ML）、線形代数のバックグラウンドを持つ人々を含む幅広い人材が、量子コンピュータ・ハードウェアのプログラミングに関する深い専門知識が無くとも、量子コンピューティングの活用を可能とします。
Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more.
About Quantum Intelligence Corp. (QIC)
Founded in 2020 by CEO Dr. Choi Hw anho and CTO Dr. Kang Hong-seok, Quantum Intelligence Corp. (QIC),based in Seoul, South Korea, is at the forefront of integrating quantum computing with artificial intelligence to revolutionize drug discovery. Using its advanced QUEST-ADMET platform and the Quantum-Dock module, QIC aims to outperform conventional drug development approaches in both accuracy and speed, offering highly precise predictions of drug efficacy and safety.
QIC's global expansion is supported by strategic partnerships, including collaborations with Oxford Quantum Circuits (UK), Quandela (France), and QuEra Computing (US), alongside a joint venture with 48Hour Discovery (Canada). These partnerships enhance QIC's presence in key North American, European and Asian markets. The collaborations are aimed at improving pharmacological predictions, discovering new drug candidates and investigating metalloprotein-ligand interactions and pharmacokinetics. Beyond healthcare, QIC is also exploring quantum computing's potential in the financial sector, aiming to transform algorithmic trading, risk analysis and asset management.
QIC's diverse team of experts in quantum physics, molecular modeling and AI is committed to driving innovations that optimize the drug development process. These efforts have established QIC as a prospective leader in quantum drug discovery, aiming to reduce development costs and timelines while improving drug safety and efficacy. The company's strategy to license out drug candidates developed with its quantum computing technology marks a paradigm shift in the pharmaceutical industry, underscoring Quantum Intelligence's potential for significant growth.
ClassiqMedia Contacts:
Michelle Allard McMahon/Jenna Beaucage
Rainier Communications
QuantumIntelligence Corp. (QIC) Media Contact:
Byung-Hoon Kim
Operations Manager, Quantum Intelligence Corp.(QIC)
Seoul, South Korea
hoon.kim@qic.ai
SEOUL, SOUTH KOREA and TEL AVIV, ISRAEL, April 4, 2024- Classiq, a leading quantum computing software company, and Quantum Intelligence Corp. (QIC, Korea) today announced the launch of innovative joint research to accelerate drug development by applying quantum computing to pharmacology. The collaboration is under the auspices of Classiq’s Quantum Computing For Life Sciences & Healthcare Center, launched with NVIDIA last year.
This new partnership is dedicated to utilizing the Classiq platform to explore the use of quantum computing in pharmacology for a wide range of predictive and analytical applications. This includes the discovery and design of novel drug candidates as well as the prediction of potential side effects and interactions. The partnership focuses on significantly enhancing the efficiency and accuracy of drug development by integrating Classiq's quantum computing platform with QIC's drug development platform.
“Quantum Intelligence diverges from the traditional route of biopharmaceutical companies, positioning it self more as a platform company powered by quantum and AI technology,” stated QIC's CEO, Hwan ho Choi, MD., PhD. “Through this unique collaborative approach, we aim to precisely identify potential side effects early on, reducing risks across all stages of drug development and clinical trials.”
QIC, a South Korean startup pioneering the QUEST-ADMET platform based on quantum computing and AI technologies, targets prediction of compound properties through electronic charge distribution algorithms, to efficiently assess therapeutic solution efficacy and safety of drug candidates.
Classiq offers a leading quantum development platform with unique technology enabling high-level abstraction that simplifies and accelerates development of efficient complex quantum software and applications. The Classiq platform’s built-in functions, GitHub repository and seamless execution on quantum computing hardware, will be key components in the research to develop pharmacology applications for research.
“This agreement marks a significant step towards a new era of accelerated drug development using quantum computing technology,” said Classiq’s CEO Nir Minerbi. “By combining Classiq's quantum computing technology with QIC's drug development platform, we target significant improvements in the efficiency and accuracy of drug development.”
Classiq について
Classiq 量子ソフトウェアのリーディングカンパニーであるテクノロジーズ社は、アルゴリズム設計から実行まで、量子コンピューティングへの入口を一本化した包括的なプラットフォーム（IDE、コンパイラ、OS）を提供しています。高レベルの記述式量子ソフトウェア開発環境は、あらゆるレベルの開発者の習熟度に対応し、量子プログラミングを自動化します。これにより、AI、ML、線形代数などのバックグラウンドを持つ幅広い人材が、量子物理学の深い専門知識を必要とすることなく、量子コンピューティングを活用することができます。Classiq 、量子コンピューティングへのアクセスを民主化し、幅広い量子ハードウェアへのアクセスを含め、量子コンピューティング革命を最大限に活用できるようにします。
高度な記述式の量子ソフトウェア開発環境は、あらゆるレベルの開発者の習熟度に対応し、量子プログラミングを自動化します。これによりAI、機械学習（ML）、線形代数のバックグラウンドを持つ人々を含む幅広い人材が、量子コンピュータ・ハードウェアのプログラミングに関する深い専門知識が無くとも、量子コンピューティングの活用を可能とします。
Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more.
About Quantum Intelligence Corp. (QIC)
Founded in 2020 by CEO Dr. Choi Hw anho and CTO Dr. Kang Hong-seok, Quantum Intelligence Corp. (QIC),based in Seoul, South Korea, is at the forefront of integrating quantum computing with artificial intelligence to revolutionize drug discovery. Using its advanced QUEST-ADMET platform and the Quantum-Dock module, QIC aims to outperform conventional drug development approaches in both accuracy and speed, offering highly precise predictions of drug efficacy and safety.
QIC's global expansion is supported by strategic partnerships, including collaborations with Oxford Quantum Circuits (UK), Quandela (France), and QuEra Computing (US), alongside a joint venture with 48Hour Discovery (Canada). These partnerships enhance QIC's presence in key North American, European and Asian markets. The collaborations are aimed at improving pharmacological predictions, discovering new drug candidates and investigating metalloprotein-ligand interactions and pharmacokinetics. Beyond healthcare, QIC is also exploring quantum computing's potential in the financial sector, aiming to transform algorithmic trading, risk analysis and asset management.
QIC's diverse team of experts in quantum physics, molecular modeling and AI is committed to driving innovations that optimize the drug development process. These efforts have established QIC as a prospective leader in quantum drug discovery, aiming to reduce development costs and timelines while improving drug safety and efficacy. The company's strategy to license out drug candidates developed with its quantum computing technology marks a paradigm shift in the pharmaceutical industry, underscoring Quantum Intelligence's potential for significant growth.
ClassiqMedia Contacts:
Michelle Allard McMahon/Jenna Beaucage
Rainier Communications
QuantumIntelligence Corp. (QIC) Media Contact:
Byung-Hoon Kim
Operations Manager, Quantum Intelligence Corp.(QIC)
Seoul, South Korea
hoon.kim@qic.ai
